As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche

The US FDA has granted priority review for Pfizer's talazoparib, which would be the fourth PARP inhibitor on the market, though only the second for breast cancer behind Lynparza. Pfizer has a long-term eye on a combination of talazoparib with its PD-L1 inhibitor Bavencio, Oncology CMO Rothenberg told Scrip at ASCO.